Skip to main content
Premium Trial:

Request an Annual Quote

Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

NEW YORK ─ Hologic said on Thursday that it has inked an agreement to acquire Mobidiag, a developer of molecular diagnostic tests and instrumentation, for approximately $795 million.

The deal includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million, Marlborough, Massachusetts-based Hologic said. It added it anticipates financing the deal with cash on hand and borrowing from an existing line of credit.

In 2020, privately held Mobidiag booked approximately $42 million in revenue. The Espoo, Finland-based company develops and markets tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections. Its automated Amplidiag and Novodiag instruments provide turnaround times ranging from 50 minutes to two hours.

Novodiag combines real-time PCR and microarrays to provide high-level multiplexing that detects multiple pathogens in a single sample, Hologic said, adding that it intends to invest in assay development for the platform.

Last month, Mobidiag announced it had received the CE mark for its Amplidiag Resp-4 molecular diagnostic test for the detection of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus.

Hologic said it anticipates that the acquisition, which it expects to close early in the fourth quarter of fiscal 2021, would be approximately $0.10 dilutive to its non-GAAP earnings per share in fiscal 2022, slightly dilutive in 2023, and accretive thereafter.

Tuomas Tenkanen, Mobidiag’s CEO, said in a statement that under Hologic, the firm "will continue to be committed to its existing customer base in Europe, including our home markets of Finland, France, Sweden, and UK. … Hologic’s commercial expertise, scale, and investment strength will accelerate the broader market adoption of our products."

The deal with Mobidiag would represent the third acquisition of a molecular diagnostics firm by Hologic in recent months. In March, it acquired Diagenode, a European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159 million. That quickly followed Hologic's completion of the acquisition of Biotheranostics, a developer of diagnostic, prognostic, and predictive cancer tests, for approximately $230 million.

"One of our key goals is to use our strong cash flow to create a larger, faster-growing company for a post-pandemic world," Steve MacMillan, Hologic's chairman, president, and CEO said in a statement. "Mobidiag provides an exceptional new growth platform, which will generate long-term value by enabling us to enter the acute care market, which is expected to roughly double in the next five years, with a differentiated, highly competitive solution."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.